Excreted urinary glycans Analysis and diagnosis of kidney disease without renal Tissue specimens(Extant-2) Study -Multicenter Prospective study-

Excreted urinary glycans Analysis and diagnosis of kidney disease without renal Tissue specimens(Extant-2) Study -Multicenter Prospective study- - Extant Prospective Study 2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040811

Enrollment

1000

Registered

2020-07-01

Start date

2020-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biopsy-proven renal diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with renal biopsy at 18 institutions (Okayama university hospital, Okayama Saiseikai General Hospital, National Hospital Organization Okayama Medical Center, Kurashiki Central Hospital, Japanese Red Cross Okayama Hospital, Japanese Red Cross Himeji Hospital, Chugoku Central Hospital, Hiroshima City Hiroshima Citizens Hospital, Onomichi Municipal Hospital, Kousei General Hospital, Ehime Prefectural Central Hospital, Matsuyama Shimin Hospital, Mitoyo General Hospital, Kagawa Prefectural Central Hospital, Kagawa Rosai Hospital, Kochi Health Sciences Center, Sumitomo Besshi Hospital and Fukuyama City Hospital) between June 2020 and March 2023.

Exclusion criteria

Exclusion criteria: 1. Patients who decline the entry of this study. 2. Patients who are regarded as inappropriate for joining this study.

Design outcomes

Primary

Measure	Time frame
Clinical performance for differentiating kidney diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Sensitivity and Specificity)	—

Secondary

Measure	Time frame
1) Clinical performance for differentiating kidney diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Accuracy and ROC-AUC) 2) Clinical performance for differentiating kidney diseases by urinary glycan profiling (Sensitivity and Specificity) 3) Clinical performance for differentiating the participants with kidney diseases in subgroups defined by eGFR (>= or <60 mL/min/1.73m2) by the combination of urinary glycan profiling and clinical tests (Sensitivity, Specificity, Accuracy, and ROC-AUC)	—

Measure

Time frame

1) Clinical performance for differentiating kidney diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Accuracy and ROC-AUC) 2) Clinical performance for differentiating kidney diseases by urinary glycan profiling (Sensitivity and Specificity) 3) Clinical performance for differentiating the participants with kidney diseases in subgroups defined by eGFR (>= or <60 mL/min/1.73m2) by the combination of urinary glycan profiling and clinical tests (Sensitivity, Specificity, Accuracy, and ROC-AUC)

—

Countries

Japan

Contacts

Public ContactYasuhiro Onishi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism

oocyst0024@gmail.com086-235-7235

Outcome results